DOCS · Doximity, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $74.8M | Fiscal 2027 First Quarter | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 47.7% | Fiscal 2027 First Quarter | — |
|
|
|||
| Free cash flow non-GAAP | $39.6M | Fiscal 2027 First Quarter | — |
|
|
|||
| Non-GAAP gross margin non-GAAP | 87.5% | Three Months Ended June 30 | — |
| Non-GAAP gross profit non-GAAP | $137.05M | Three Months Ended June 30 | — |
| Non-GAAP net income non-GAAP | $54.95M | Three Months Ended June 30 | — |
| Non-GAAP net income margin non-GAAP | 35.1% | Three Months Ended June 30 | — |
| Non-GAAP operating income non-GAAP | $72.43M | Three Months Ended June 30 | — |
| active prescribers | 800,000 | Q4 fiscal 2026 | — |
| Operating cash flow | $326.5M | Fiscal Year 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DOCS
this stock
Doximity, Inc.
|
$4.42B | -44.0% | +13.1% | 29.5 | 13.8% |
|
VEEV
Veeva Systems Inc
|
$39.60B | +9.2% | +28.1% | 43.2 | 4.5% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$14.08B | -18.8% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$12.21B | +64.8% | +28.2% | 37.4 | 4.2% |
|
TEM
Tempus AI, Inc.
|
$9.40B | -11.8% | +83.4% | — | 18.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DOCS | -9.5% | +15.2% | +4.4% | +18.6% | -44.0% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -9.9% | +10.8% | -9.4% | +14.7% | -57.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.